✦ LIBER ✦
232: Phase 2b/3 Trial Design and Baseline Patient Characteristics of a Study to Determine Effects of Bardoxolone Methyl (BARD) in Patients With Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD)
✍ Scribed by P.E. Pergola; E.B. Grossman; C. Meyer; B. Richardson; D. Warnock
- Book ID
- 114469794
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 96 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0272-6386
No coin nor oath required. For personal study only.